Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07217379 · ClinicalTrials.gov registry record · Phase 1
The DART DELIVER-02 Study
A Phase 1 study of HIV (Human Immunodeficiency Virus), sponsored by University of North Carolina, Chapel Hill.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 3
- Study locations
NCT07217379 is a Phase 1 study of HIV (Human Immunodeficiency Virus) that is actively recruiting participants, run by University of North Carolina, Chapel Hill. The registered enrollment target is 24 participants, below the 80-participant average among 4 other HIV (Human Immunodeficiency Virus) trials with a reported enrollment target (70% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT07217379, a Phase 1 study of HIV (Human Immunodeficiency Virus), is actively recruiting participants, sponsored by University of North Carolina, Chapel Hill.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 3
- Study locations
Study Summary
This research study aims to find out how safe and well tolerated the experimental study drugs are when given to persons with HIV (PWH) taking antiretroviral therapy (ART). The study treatments are MGD014 and MGD020, which are two antibodies developed specifically for HIV, and Vorinostat, an oral medication to help expose HIV in cells to the antibodies. The study will measure the impact of study treatment on non-active HIV in cells, and how long MGD014 and MGD020 stay in the body after they are given. In this study, participants will be randomly assigned to one of three groups. All participants receive MGD014 and MGD020, given sequentially as infusions through an IV for 4 doses. Participants in one group (group A) receive only MGD014 and MGD020. Participants in another group (group B) will stop taking their ART therapy for up to 8 weeks (a temporary treatment interruption (TTI)) while receiving MGD014 and MGD020. Participants in the third group (group C) receive Vorinostat in addition to MGD014 and MGD020. Total time of participation is about 8 months and involves 13 or 18 visits, depending on group assignment.
Conditions Studied
Interventions
- DRUG Vorinostat
- DRUG MGD020
- DRUG MGD014
- OTHER Temporary treatment interruption
Study Locations (3)
Other
- Moi University Clinical Research Center - Eldoret
- Kenya Medical Research Institute/Walter Reed Project - Kericho
North Carolina
- University of North Carolina - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2025-10-02 |
| Est. Completion | 2027-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07217379
The ClinicalTrials.gov registry entry for NCT07217379 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 80-participant average among 4 other HIV (Human Immunodeficiency Virus) trials with a reported enrollment target (70% lower). The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV (Human Immunodeficiency Virus) appearing as the primary indexed condition, and to 4 interventions - of which Vorinostat is the first listed.
NCT07217379 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Other, North Carolina.
Frequently Asked Questions
What is clinical trial NCT07217379 about?
NCT07217379 is a clinical study titled "The DART DELIVER-02 Study". This research study aims to find out how safe and well tolerated the experimental study drugs are when given to persons with HIV (PWH) taking antiretroviral therapy (ART). The study treatments are MGD014 and MGD020, which are two antibodies developed specifically for HIV, and Vorinostat, an oral med...
What is the current status of trial NCT07217379?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2025-10-02. Estimated completion is 2027-02.
What conditions does trial NCT07217379 study?
This clinical trial studies the following conditions: HIV (Human Immunodeficiency Virus).
What interventions are being tested in trial NCT07217379?
The interventions under investigation include: Vorinostat (DRUG), MGD020 (DRUG), MGD014 (DRUG), Temporary treatment interruption (OTHER).
Who is sponsoring clinical trial NCT07217379?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07217379 being conducted?
This trial has 3 study locations across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV (Human Immunodeficiency Virus)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Guaranteed Income to Boost HIV Care Continuity and Suppression Post-Jail Release
RECRUITING · NA
-
Pre-exposure Prophylaxis (PrEP) for Health
RECRUITING · NA
-
Effect of Diet-induced Weight Loss on HIV-associated Metabolic Syndrome
COMPLETED · NA
-
TechMPower: Advancing HIV/SUD Care and Service Delivery for People in Re-entry
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.